China Fast-Tracks Multiple HCV Drugs With Access In Mind
This article was originally published in PharmAsia News
Executive Summary
All eyes on a list of selected oral hepatitis C drugs that are expected to win out in China's notoriously lengthy approval battle, amid a potentially huge opening as Chinese HCV patients switch from interferon to all oral therapies.
You may also be interested in...
Sweeping China Policy Reforms Seen Bolstering Domestic Generics
Off-patent original drugs in China are set to face unprecedented competition as the country drives up policy support for high-quality, bioequivalent domestic generics, and outlines other sweeping moves covering pricing and compulsory licenses.
Sweeping China Policy Reforms Seen Bolstering Domestic Generics
Off-patent original drugs in China are set to face unprecedented competition as the country drives up policy support for high-quality, bioequivalent domestic generics, and outlines other sweeping moves covering pricing and compulsory licenses.
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
ARCH invests $150m in the Scangos-led Vir Biotechnology; Flagship recruits ex-Novartis executive Epstein; Versant closes a new $400m fund; and $601.1m in 11 other recent VC funding rounds.